Files and links (1)
Published, Version of Record (VoR)CC BY-NC V4.0, Open
Journal article
Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
Molecular diagnosis & therapy, v 22(5), pp 571-593
01 Oct 2018
PMID: 30039193
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Autism spectrum disorder (ASD) affects similar to 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may affect a significant subset of children with ASD. Here we systematically review the literature on human studies of mitochondrial dysfunction related to ASD. Clinical aspects of mitochondrial dysfunction in ASD include unusual neurodevelopmental regression, especially if triggered by an inflammatory event, gastrointestinal symptoms, seizures, motor delays, fatigue and lethargy. Traditional biomarkers of mitochondrial disease are widely reported to be abnormal in ASD, but appear non-specific. Newer biomarkers include buccal cell enzymology, biomarkers of fatty acid metabolism, non-mitochondrial enzyme function, apoptosis markers and mitochondrial antibodies. Many genetic abnormalities are associated with mitochondrial dysfunction in ASD, including chromosomal abnormalities, mitochondrial DNA mutations and large-scale deletions, and mutations in both mitochondrial and non-mitochondrial nuclear genes. Mitochondrial dysfunction has been described in immune and buccal cells, fibroblasts, muscle and gastrointestinal tissue and thebrains of individuals with ASD. Several environmental factors, including toxicants, microbiome metabolites and an oxidized microenvironment are shown to modulate mitochondrial function in ASD tissues. Investigations of treatments for mitochondrial dysfunction in ASD are promising but preliminary. The etiology of mitochondrial dysfunction and how to define it in ASD is currently unclear. However, preliminary evidence suggests that the mitochondria may be a fruitful target for treatment and prevention of ASD. Further research is needed to better understand the role of mitochondrial dysfunction in the pathophysiology of ASD.
Metrics
Details
- Title
- Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
- Creators
- Shannon Rose - University of Arkansas for Medical SciencesDmitriy M. Niyazov - Ochsner Hlth Syst, Sect Med Genet, New Orleans, LA USADaniel A. Rossignol - Rossignol Medical Center, Aliso Viejo, CA, USA.Michael Goldenthal - St. Christopher's Hospital for ChildrenStephen G. Kahler - University of Arkansas for Medical SciencesRichard E. Frye - Barrow Neurological Institute
- Publication Details
- Molecular diagnosis & therapy, v 22(5), pp 571-593
- Publisher
- Springer Nature
- Number of pages
- 23
- Grant note
- Phoenix Children's Hospital Foundation (Phoenix, AZ) Jane Bostford Johnson Foundation (New York, NY) Autism Research Institute (San Diego, CA) Jager Family Foundation (Chicago, IL) Arkansas Biosciences Institute (Little Rock, AR, USA) Gupta Family Foundation (Atherton, CA) Jonty Foundation (St. Paul, MN)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000444004500006
- Scopus ID
- 2-s2.0-85050534203
- Other Identifier
- 991019168495804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Genetics & Heredity
- Pharmacology & Pharmacy